T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

导出 OA

翻译打印收藏纠错

作者： Tori N,Yamamoto ^[1] ; Ping-Hsien,Lee ^[2] ; Suman K,Vodnala ^[3] ; Devikala,Gurusamy ^[1] ; Rigel J,Kishton ^[2] ; Zhiya,Yu ^[1] ; Arash,Eidizadeh ^[2] ; Robert,Eil ^[1] ; Jessica,Fioravanti ^[2] ; Luca,Gattinoni ^[1] ; James N,Kochenderfer ^[2] ; Terry J,Fry ^[1] ; Bulent Arman,Aksoy ^[2] ; Jeffrey E,Hammerbacher ^[1] ; Anthony C,Cruz ^[2] ; Richard M,Siegel ^[4] ; Nicholas P,Restifo ^[5] ; Christopher A,Klebanoff ^[5]

作者单位： Center for Cancer Research and. ^[1] Center for Cell-Based Therapy, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA. ^[2] Immunology Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania, USA. ^[3] Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA. ^[4] Experimental Transplantation and Immunology Branch, NCI, NIH, Bethesda, Maryland, USA. ^[5] Children's Hospital Colorado, University of Colorado Denver, Aurora, Colorado, USA. ^[6] Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA. ^[7] National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA. ^[8] Parker Institute for Cancer Immunotherapy, New York, New York, USA. ^[9] Center for Cell Engineering and Department of Medicine, MSKCC, New York, New York, USA. ^[10] Weill Cornell Medical College, New York, New York, USA. ^[11]

关键词 Cancer gene therapy Cancer immunotherapy Immunology Oncology